ATTO Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $450.00K; Research and development $18.95M; Operating expenses $22.25M; Net income -$20.69M.
- 2026-03-31: Revenue (m); Research and development (m); Operating expenses (m); Net income -$18.66M.
- 2025-06-30: Revenue $0.00; Research and development $13.59M; Operating expenses $16.62M; Net income -$14.44M.
- 2025-03-31: Revenue (m); Research and development (m); Operating expenses (m); Net income -$15.15M.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Research and development | Operating expenses | Net income |
|---|---|---|---|---|
| 2026-06-30 | $450.00K | $18.95M | $22.25M | -$20.69M |
| 2026-03-31 | (m) | (m) | (m) | -$18.66M |
| 2025-06-30 | $0.00 | $13.59M | $16.62M | -$14.44M |
| 2025-03-31 | (m) | (m) | (m) | -$15.15M |
Revenue and expense 6 month
| Period end | Revenue | Research and development | Operating expenses | Net income |
|---|---|---|---|---|
| 2026-06-30 | $450.00K | $35.69M | $42.21M | -$39.34M |
| 2025-06-30 | $0.00 | $25.44M | $32.72M | -$29.59M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |